References
- Globocan 2008Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008 Available from: http://globocan.iarc.frAccessed January 13, 2013
- KimGPSargentDJMahoneyMRPhase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841J Clin Oncol2009272848285419380443
- KoopmanMAntoniniNFDoumaJSequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trialLancet200737013514217630036
- TolJKoopmanMCatsARodenburgCJChemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancerN Engl J Med200936056357219196673
- WangTFLockhartACAflibercept in the treatment of metastatic colorectal cancerClin Med Insights Oncol20126193022253552
- TakahashiSVascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapyBiol Pharm Bull2011341785178822130231
- HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
- KabbinavarFFHambletonJMassRDHurwitzHIBergslandESarkarSCombined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol2005233706371215867200
- SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol2008262013201918421054
- GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol2007251539154417442997
- CohenMHGootenbergJKeeganPPazdurRFDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerOncologist20071235636117405901
- EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer20094522824719097774
- Cancer Therapy Evaluation ProgramCommon terminology criteria for adverse events v 3.0 (CTCAE)2006 Available from: http://www.eortc.be/services/doc/ctc/ctcaev3.pdfAccessed February 28, 2013
- CassidyJClarkeSDíaz-RubioEXELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated resultsBr J Cancer2011105586421673685
- TolJKoopmanMRodenburgCJA randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicityAnn Oncol20081973473818272912
- ToshihikoDoiNarikazuBokuKenKatoPhase I/II study of Capecitabine plus Oxaliplatin (XELOX) plus Bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancerJpn J Clin Oncol2010401091392020462981
- GuanZZXuJMLuoRCEfficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trialChin J Cancer20113068268921959045
- KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med20083591757176518946061
- LièvreABachetJBBoigeVKRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximabJ Clin Oncol20082637437918202412
- HechtJRMitchellEChidiacTA randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol20092767228019114685
- GrotheyASargentDGoldbergRMSchmollHJSurvival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentJ Clin Oncol2004221209121415051767
- ParkLCLeeHSShinSHBevacizumab as a second- or later-line of treatment for metastatic colorectal cancerWorld J Gastroenterol2012181104110922416186
- LièvreASamalinEMitryEBevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyBMC Cancer2009934719785749